{
  "id": 21287442,
  "title": "Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors",
  "url": "https://urgent.news/2026/11/22/stoke-therapeutics-3-key-takeaways-for-long-term-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T21:00:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/takeaways/2026/11/22/stoke-therapeutics-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "1. Stoke Therapeutics (STOK) has secured alignment with the FDA on a composite endpoint for their lead drug candidate, Zorevunersen, specifically for treating Dravet syndrome. This agreement confirms the approval pathway for the experimental medicine, targeting a rare genetic epilepsy with high unmet medical need, and strengthens prospects for potential approval and launch in early 2028.\n\n2. The New Drug Application (NDA) submission for Zorevunersen will incorporate a combined cognitive and behavioral assessment. The FDA has agreed to evaluate key secondary endpoints using four subdomains from the Vineland-3, an adaptive behavior scale, which will provide a multicomponent assessment of cognitive and behavioral changes.\n\n3. The EMPEROR Phase III registrational trial enrolled 162 patients without any discontinuations, signaling strong caregiver commitment to the clinical program. Management identifies over 6,000 addressable pediatric patients in the U.S. living with Dravet syndrome, with approximately half receiving treatment at 50 specialized medical centers experienced in intrathecal delivery. These centers, which make up over half of the identified U.S. sites, have participated in a Zorevunersen study. Cash reserves of $358.8 million and reimbursements from Biogen will fund operations into early 2028, providing multiyear funding through the expected commercial launch.",
  "summary": "Concentrated treatment at 50 specialized centers may position the company to scale efficiently once Zorevunersen reaches the market.",
  "key_points": [
    "NDA submission includes cognitive and behavioral assessments via Vineland-3 scale.",
    "EMPEROR Phase III trial of 162 patients shows strong caregiver commitment and $358.8M cash reserves."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors",
        "url": "https://urgent.news/2026/11/22/stoke-therapeutics-3-key-takeaways-for-long-term-investors-21295951",
        "published": "2026-11-22T21:20:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}